Skip to main content
. 2023 Apr 20;11(4):1079. doi: 10.3390/microorganisms11041079

Table 1.

Basal characteristics and clinical and analytical data in patients with and without nosocomial infections.

Variable Total (n = 69) Noninfected = 40 (58%) Infected = 29 (42.0%) p
Baseline Characteristics
Sex, male (%) 57 (82.7%) 31 (77.5) 26 (89.7) 0.218
Age, median years (IQR) 58 (50.5–62.8) 59 (50–64.5) 55 (50.6–61.1) 0.491
Underlying conditions (%):
BMI > 25 kg/m2 35 (50.7) 20 (50) 15 (51.7) 0.999
Arterial hypertension 33 (49.3) 16 (42.1) 17 (58.6) 0.222
Cigarette smoking * 26 (38.8) 12 (31.6) 14 (48.3) 0.365
Stopped smoking > 5 years 13 (19.4) 9 (23.7) 4 (13.8) 0.365
Dyslipidemia 27 (40.3) 13 (34.2) 14 (48.3) 0.317
Peripheric vascular disease 7 (10.4) 4 (10.5) 3 (10.3) 0.999
Cardiac disease 52 (75.4) 25 (62.5) 27 (93.1) 0.004
Chronic pulmonary disease 8 (11.8) 5 (12.5) 3 (10.7) 0.999
Diabetes mellitus 19 (27.5) 9 (22.5) 10 (34.5) 0.290
Liver cirrhosis 1 (1.4) 0 1 (3.4) 0.420
Chronic kidney failure 9 (13) 3 (7.5) 6 (20.7) 0.152
Chronic renal replacement 0 05 (12.5) 0 -
Immunosuppression: 10 (14.5) 5 (17.2) 0.732
HIV infection (<200 CD4+) 0
Solid tumor with active CT 0 0 0 -
HT neoplasia/HSCT (<5 yrs) 0 3 (7.5) 0 -
Solid organ transplant 3 (4.3) 0 0 0.258
IS therapy/corticosteroids 2 (2.9) 2 (5) 2 (6.9) 0.173
Autoimmune disease 6 (8.7) 2 (5) 4 (13.8) 0.230
5 (7.2) 0 3 (10.3) 0.643
0 0 -
Clinical and analytical data before ECMO
Lactic acid prior to ECMO 8.1 (4.9–12.2) 8.7 (4.75–13.6) 7.6 (5–10.7) 0.202
Serum creatinine prior to ECMO 1 (0.9–1.3) 0.9 (0.8–1.2) 1.2 (0.9–1.6) 0.027
Days of MV before ECMO 1.3 (0.6–2.0) 1.3 (0.9–1.9) 2 (0.5–5.5) 0.930
Ejective fraction (%) prior to ECMO 18.1 (11.3–30.8) 19.1 (10.8–34.2) 17.3 (11.7–25.6) 0.374
RBC requirement before ECMO
(5 U) (%)
3 (4.3) 3 (7.5) 0 0.258
Type of failure (%)
Cardiac 62 (89.9) 36 (90) 26 (89.7) 0.999
Cardiac + respiratory 5 (7.2) 3 (7.5) 2 (6.9) 0.999
Respiratory 2 (2.9) 1 (2.5) 1 (2.5) 0.999
ECMO indication:
Cardiogenic shock 38 (55.1) 21 (52.5) 17 (58.6) 0.634
Myocarditis 1 (1.4) 1 (2.5) 0 0.999
End-stage heart failure 0 0 0 -
Cardiac arrest 21 (30.4) 11 (27.5) 10 (34.5) 0.601
Pulmonary embolism 8 (11.6) 6 (15) 2 (6.9) 0.453
Arrhythmic storm 13 (18.8) 8 (20) 5 (17.2%) 0.999
ECMO as bridge to heart Tx (%) 9 (13%) 5 (12.5) 4 (13.8) 0.999
Cardiac arrest in the last 24 h (%) 44 (66.7) 26 (70.3) 18 (62.1) 0.600
SOFA score 7.9 (5.8–10.4) 8.2 (6.30–10.0) 7.0 (5.4–10.4) 0.537
Charlson comorbidity score 2.8 (1.9–3.7) 3 (2.0–4.0) 2.7 (1.86–3.6) 0.557
Major surgery before ECMO (%) 2 (2.9) 2 (5) 0 0.506
Colonization before ECMO (%) 21 (30.4) 10 (25) 11 (37.9) 0.295
MDR colonization 0 0 0 -
Any infection before ECMO (%) 10 (14.5) 9 (22.5) 1 (3.4) 0.037
Antibiotics >24 h before ECMO (%) 7 (5.2) 2 (5) 3 (10.3) 0.643

BMI: body mass index, IS: immunosuppressive, CT: chemotherapy, Yrs: years, HSCT: hematopoietic stem cell transplant, HT: hematologic neoplasia, MV: mechanical ventilation, RBC: red blood cells, Tx: transplant.